Cetrorelix

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Cetrorelix

Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Subcutaneous injection
ATC code	H01CC02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	85%
Protein binding	86%
Elimination half-life	62.8 hours / 3mg single dose
Excretion	Liver
Identifiers
IUPAC name Acetyl-D-3-(2´-naphtyl)-alanine- D-4-chlorophenylalanine-D-3-(3´-pyridyl)- alanine-L-serine-L-tyrosine-D-citruline-L- leucine-L-arginine-L-proline-D- alanine-amide
CAS Number	120287-85-6
DrugBank	APRD00686
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Molar mass	1431.06 g/mol

WikiDoc Resources for Cetrorelix
Articles
Most recent articles on Cetrorelix Most cited articles on Cetrorelix Review articles on Cetrorelix Articles on Cetrorelix in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cetrorelix Images of Cetrorelix Photos of Cetrorelix Podcasts & MP3s on Cetrorelix Videos on Cetrorelix
Evidence Based Medicine
Cochrane Collaboration on Cetrorelix Bandolier on Cetrorelix TRIP on Cetrorelix
Clinical Trials
Ongoing Trials on Cetrorelix at Clinical Trials.gov Trial results on Cetrorelix Clinical Trials on Cetrorelix at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cetrorelix NICE Guidance on Cetrorelix NHS PRODIGY Guidance FDA on Cetrorelix CDC on Cetrorelix
Books
Books on Cetrorelix
News
Cetrorelix in the news Be alerted to news on Cetrorelix News trends on Cetrorelix
Commentary
Blogs on Cetrorelix
Definitions
Definitions of Cetrorelix
Patient Resources / Community
Patient resources on Cetrorelix Discussion groups on Cetrorelix Patient Handouts on Cetrorelix Directions to Hospitals Treating Cetrorelix Risk calculators and risk factors for Cetrorelix
Healthcare Provider Resources
Symptoms of Cetrorelix Causes & Risk Factors for Cetrorelix Diagnostic studies for Cetrorelix Treatment of Cetrorelix
Continuing Medical Education (CME)
CME Programs on Cetrorelix
International
Cetrorelix en Espanol Cetrorelix en Francais
Business
Cetrorelix in the Marketplace Patents on Cetrorelix
Experimental / Informatics
List of terms related to Cetrorelix

Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily or weekly subcutaneous injection.

Cetrorelix is marketed by Solvay Pharmaceuticals as Cetrotide.